Literature DB >> 30409908

Chaperome heterogeneity and its implications for cancer study and treatment.

Tai Wang1, Anna Rodina1, Mark P Dunphy2, Adriana Corben3, Shanu Modi4, Monica L Guzman5, Daniel T Gewirth6, Gabriela Chiosis7,4.   

Abstract

The chaperome is the collection of proteins in the cell that carry out molecular chaperoning functions. Changes in the interaction strength between chaperome proteins lead to an assembly that is functionally and structurally distinct from each constituent member. In this review, we discuss the epichaperome, the cellular network that forms when the chaperome components of distinct chaperome machineries come together as stable, functionally integrated, multimeric complexes. In tumors, maintenance of the epichaperome network is vital for tumor survival, rendering them vulnerable to therapeutic interventions that target critical epichaperome network components. We discuss how the epichaperome empowers an approach for precision medicine cancer trials where a new target, biomarker, and relevant drug candidates can be correlated and integrated. We introduce chemical biology methods to investigate the heterogeneity of the chaperome in a given cellular context. Lastly, we discuss how ligand-protein binding kinetics are more appropriate than equilibrium binding parameters to characterize and unravel chaperome targeting in cancer and to gauge the selectivity of ligands for specific tumor-associated chaperome pools.
© 2019 Wang et al.

Entities:  

Keywords:  70 kilodalton heat shock protein (Hsp70); biomarker; cancer biology; cancer therapy; chaperome; chaperone; chemical biology; chemical probes; epichaperome; heat shock protein 90 (Hsp90); protein networks; stress response

Mesh:

Substances:

Year:  2018        PMID: 30409908      PMCID: PMC6369301          DOI: 10.1074/jbc.REV118.002811

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  137 in total

1.  Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.

Authors:  Pallav D Patel; Pengrong Yan; Paul M Seidler; Hardik J Patel; Weilin Sun; Chenghua Yang; Nanette S Que; Tony Taldone; Paola Finotti; Ralph A Stephani; Daniel T Gewirth; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2013-09-01       Impact factor: 15.040

Review 2.  Expanding the cellular molecular chaperone network through the ubiquitous cochaperones.

Authors:  Frank J Echtenkamp; Brian C Freeman
Journal:  Biochim Biophys Acta       Date:  2011-08-24

Review 3.  The Hsp70 and Hsp60 chaperone machines.

Authors:  B Bukau; A L Horwich
Journal:  Cell       Date:  1998-02-06       Impact factor: 41.582

4.  Perturbations in maturation of secretory proteins and their association with endoplasmic reticulum chaperones in a cell culture model for epithelial ischemia.

Authors:  G Kuznetsov; K T Bush; P L Zhang; S K Nigam
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

5.  Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.

Authors:  Neha Bhagwat; Priya Koppikar; Matthew Keller; Sachie Marubayashi; Kaitlyn Shank; Raajit Rampal; Jun Qi; Maria Kleppe; Hardik J Patel; Smit K Shah; Tony Taldone; James E Bradner; Gabriela Chiosis; Ross L Levine
Journal:  Blood       Date:  2014-01-27       Impact factor: 22.113

Review 6.  Proteomic interrogation of HSP90 and insights for medical research.

Authors:  Lorenz Weidenauer; Tai Wang; Suhasini Joshi; Gabriela Chiosis; Manfredo R Quadroni
Journal:  Expert Rev Proteomics       Date:  2017-10-16       Impact factor: 3.940

7.  Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.

Authors:  Jeffrey R Huth; Chang Park; Andrew M Petros; Aaron R Kunzer; Michael D Wendt; Xilu Wang; Christopher L Lynch; Jamey C Mack; Kerry M Swift; Russell A Judge; Jun Chen; Paul L Richardson; Sha Jin; Stephen K Tahir; Edward D Matayoshi; Sarah A Dorwin; Uri S Ladror; Jean M Severin; Karl A Walter; Diane M Bartley; Stephen W Fesik; Steven W Elmore; Philip J Hajduk
Journal:  Chem Biol Drug Des       Date:  2007-07       Impact factor: 2.817

Review 8.  Design strategies to address kinetics of drug binding and residence time.

Authors:  Kevin P Cusack; Ying Wang; Michael Z Hoemann; Jasmina Marjanovic; Roland G Heym; Anil Vasudevan
Journal:  Bioorg Med Chem Lett       Date:  2015-03-05       Impact factor: 2.823

9.  Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes.

Authors:  Tony Taldone; Anna Rodina; Erica M DaGama Gomes; Matthew Riolo; Hardik J Patel; Raul Alonso-Sabadell; Danuta Zatorska; Maulik R Patel; Sarah Kishinevsky; Gabriela Chiosis
Journal:  Beilstein J Org Chem       Date:  2013-03-15       Impact factor: 2.883

Review 10.  Molecular cochaperones: tumor growth and cancer treatment.

Authors:  Stuart K Calderwood
Journal:  Scientifica (Cairo)       Date:  2013-04-17
View more
  21 in total

Review 1.  A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Authors:  Tony Taldone; Tai Wang; Anna Rodina; Naga Vara Kishore Pillarsetty; Chander S Digwal; Sahil Sharma; Pengrong Yan; Suhasini Joshi; Piyusha P Pagare; Alexander Bolaender; Gail J Roboz; Monica L Guzman; Gabriela Chiosis
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

2.  Chemical probes and methods for single-cell detection and quantification of epichaperomes in hematologic malignancies.

Authors:  Swathi Merugu; Sahil Sharma; Justin Kaner; Chander Digwal; Mayumi Sugita; Suhasini Joshi; Tony Taldone; Monica L Guzman; Gabriela Chiosis
Journal:  Methods Enzymol       Date:  2020-05-10       Impact factor: 1.600

Review 3.  Molecular chaperones and protein quality control: an introduction to the JBC Reviews thematic series.

Authors:  Johannes Buchner
Journal:  J Biol Chem       Date:  2019-01-09       Impact factor: 5.157

4.  First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.

Authors:  Mark P S Dunphy; Christina Pressl; Nagavarakishore Pillarsetty; Milan Grkovski; Shanu Modi; Komal Jhaveri; Larry Norton; Bradley J Beattie; Pat B Zanzonico; Danuta Zatorska; Tony Taldone; Stefan O Ochiana; Mohammad M Uddin; Eva M Burnazi; Serge K Lyashchenko; Clifford A Hudis; Jacqueline Bromberg; Heiko M Schöder; Josef J Fox; Hanwen Zhang; Gabriela Chiosis; Jason S Lewis; Steven M Larson
Journal:  Clin Cancer Res       Date:  2020-05-04       Impact factor: 12.531

5.  A robust strategy for proteomic identification of biomarkers of invasive phenotype complexed with extracellular heat shock proteins.

Authors:  Steven G Griffiths; Alan Ezrin; Emily Jackson; Lisa Dewey; Alan A Doucette
Journal:  Cell Stress Chaperones       Date:  2019-10-24       Impact factor: 3.667

Review 6.  Chaperome Networks - Redundancy and Implications for Cancer Treatment.

Authors:  Pengrong Yan; Tai Wang; Monica L Guzman; Radu I Peter; Gabriela Chiosis
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  Mortalin (HSPA9) facilitates BRAF-mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability.

Authors:  Pui-Kei Wu; Seung-Keun Hong; Wenjing Chen; Andrew E Becker; Rebekah L Gundry; Chien-Wei Lin; Hao Shao; Jason E Gestwicki; Jong-In Park
Journal:  Sci Signal       Date:  2020-03-10       Impact factor: 8.192

8.  NECA derivatives exploit the paralog-specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90.

Authors:  John D Huck; Nanette L S Que; Robert M Immormino; Liza Shrestha; Tony Taldone; Gabriela Chiosis; Daniel T Gewirth
Journal:  J Biol Chem       Date:  2019-09-09       Impact factor: 5.157

9.  Neutral analogs of the heat shock protein 70 (Hsp70) inhibitor, JG-98.

Authors:  Hao Shao; Jason E Gestwicki
Journal:  Bioorg Med Chem Lett       Date:  2020-01-11       Impact factor: 2.823

10.  Paradigms for Precision Medicine in Epichaperome Cancer Therapy.

Authors:  Nagavarakishore Pillarsetty; Komal Jhaveri; Tony Taldone; Eloisi Caldas-Lopes; Blesida Punzalan; Suhasini Joshi; Alexander Bolaender; Mohammad M Uddin; Anna Rodina; Pengrong Yan; Anson Ku; Thomas Ku; Smit K Shah; Serge Lyashchenko; Eva Burnazi; Tai Wang; Nicolas Lecomte; Yelena Janjigian; Anas Younes; Connie W Batlevi; Monica L Guzman; Gail J Roboz; Jacek Koziorowski; Pat Zanzonico; Mary L Alpaugh; Adriana Corben; Shanu Modi; Larry Norton; Steven M Larson; Jason S Lewis; Gabriela Chiosis; John F Gerecitano; Mark P S Dunphy
Journal:  Cancer Cell       Date:  2019-10-24       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.